inflammatori
injuri
suffer
alveolar
epitheliumendothelium
complex
provid
multipl
potenti
therapeut
target
inflammatori
process
could
inhibit
stage
genom
inflammatori
signal
leukocyt
activ
similarli
variou
pathophysiolog
consequ
alveolar
injuri
could
amen
pharmacolog
intervent
injuri
process
affect
local
alveolar
ventil
ga
diffus
perfus
lead
reduc
complianc
ventilationperfus
mismatch
respiratori
failur
chapter
review
evid
past
present
potenti
futur
pharmacolog
therapi
acut
lung
injuri
acut
respiratori
distress
syndrom
aliard
therapi
classifi
aim
improv
pathophysiolog
consequ
aliard
antiinflammatori
although
larg
degre
overlap
exist
surfact
endogen
mixtur
phospholipid
protein
produc
type
alveolar
cell
reduc
alveolar
surfac
tension
prevent
alveolar
collaps
antiinflammatori
antimicrobi
properti
exogen
surfact
administr
success
use
neonat
respiratori
distress
syndrom
condit
reduc
surfact
product
earli
trial
ard
demonstr
physiolog
improv
howev
later
phase
trial
fail
show
improv
mortal
metaanalysi
surfact
trial
ali
ard
report
increas
oxygen
without
improv
durat
ventil
mortal
variou
reason
propos
result
although
neonat
syndrom
due
reduc
product
situat
complex
aliard
surfact
affect
increas
remov
alter
composit
reduc
efficaci
reduc
product
potenti
limit
phase
studi
includ
use
suboptim
surfact
formul
dose
durat
therapi
inadequ
alveolar
deliveri
late
initi
therapi
effect
calfact
calf
protein
b
cbase
surfact
aliard
current
studi
wherea
trial
surfaxin
synthet
protein
bbase
surfact
pig
protein
b
cbase
surfact
recent
termin
result
await
pend
new
research
surfact
therapi
recommend
alveolar
flood
primarili
depend
three
factor
capillari
hydrostat
pressur
oncot
pressur
alveolarcapillari
permeabl
capillari
permeabl
increas
aliard
reduc
hydrostat
pressur
increas
oncot
pressur
may
amelior
develop
pulmonari
edema
reduc
capillari
hydrostat
pressur
target
pulmonari
arteri
occlus
pressur
paop
central
venou
pressur
cvp
may
associ
improv
outcom
aliard
although
fluid
manag
guid
pulmonari
arteri
cathet
pac
compar
central
venou
cathet
offer
advantag
aliard
posit
fluid
balanc
increas
extravascular
lung
water
evlw
associ
poor
outcom
ard
guid
fluid
therapi
evlw
measur
rather
paop
may
better
hydrostat
pressur
may
reduc
restrict
fluid
intak
increas
fluid
output
either
diuret
renal
replac
therapi
rrt
decreas
vasomotor
tone
vasodil
phase
fluid
cathet
treatment
trial
factt
studi
demonstr
improv
secondari
outcom
durat
ventil
intens
care
unit
icu
stay
restrict
fluid
strategi
fluid
balanc
dictat
protocol
diuret
administr
base
fill
pressur
total
fluid
balanc
ml
compar
ml
liber
fluid
strategi
although
differ
mortal
importantli
increas
renal
failur
organ
hypoperfus
fluid
restrict
anim
model
demonstr
reduc
pulmonari
edema
reduct
pulmonari
vascular
pressur
permeabl
rrt
two
small
observ
studi
human
provid
mix
result
ten
children
aliard
bone
marrow
transplant
chemotherapi
treat
rrt
surviv
rate
contrast
histor
surviv
rate
thirtyseven
adult
renal
failur
aliard
treat
rrt
zero
fluid
balanc
pulmonari
improv
within
first
hour
treatment
role
rrt
manag
aliard
remain
uncertain
choic
fluid
resuscit
aliard
remain
unclear
theoret
colloid
higher
oncot
pressur
would
suitabl
crystalloid
born
larg
trial
albumin
versu
salin
critic
ill
hypoproteinemia
associ
develop
lung
injuri
marker
weight
gain
death
two
small
studi
investig
use
furosemid
albumin
infus
hypoproteinem
patient
ali
show
increas
total
serum
protein
neg
fluid
balanc
furosemid
albumin
administr
associ
improv
oxygen
mortal
benefit
albumin
also
exert
antioxid
effect
thiol
group
nonsurvivor
aliard
reduc
thiol
valu
infus
albumin
associ
increas
plasma
thiol
level
sepsi
aliard
decreas
marker
oxid
injuri
studi
present
ongo
investig
whether
minim
evlw
measur
transpulmonari
thermal
indic
dilut
use
puls
contour
cardiac
output
picco
direct
factt
diuret
algorithm
superior
cvpguid
therapi
phase
studi
investig
role
recombin
human
atrial
natriuret
peptid
carperitid
minim
pulmonari
edema
ard
recent
complet
result
await
lung
injuri
often
herald
rise
pulmonari
vascular
resist
imbal
pulmonari
vasoconstrictor
vasodil
seen
anim
endotoxin
shock
model
intraven
adenosin
reduc
evlw
wherea
intraven
nitroprussid
nitroglycerin
also
reduc
pulmonari
edema
gener
expens
increas
ventilationperfus
mismatch
date
clear
evid
support
role
vasodil
treatment
aliard
alveolar
fluid
clearanc
afc
impair
patient
aliard
group
higher
mortal
rate
bagonist
upregul
afc
increas
sodium
ion
transport
alveolar
space
clinic
trial
intraven
salbutamol
aliard
demonstr
reduc
evlw
trend
toward
increas
surviv
retrospect
studi
salbutamol
exposur
ali
suggest
associ
higher
exposur
improv
outcom
b
agonist
may
exert
sever
benefici
effect
aliard
includ
increas
surfact
secret
decreas
lung
endotheli
permeabl
decreas
airway
resist
decreas
airway
pressur
larg
unit
kingdom
multicent
studi
progress
examin
effect
intraven
salbutamol
outcom
aliard
wherea
acut
respiratori
distress
syndrom
network
ardsnet
inhal
bagonist
studi
recent
termin
result
await
bagonist
current
recommend
treatment
aliard
anoth
potenti
futur
treatment
gene
therapi
increas
express
ion
channel
pump
need
afc
anim
studi
investig
overexpress
b
subunit
sodiumpotassium
adenosin
triphosphatas
atpas
pump
demonstr
increas
rate
afc
improv
surviv
alveolar
epithelium
sever
injur
cellular
regener
may
requir
function
epitheli
layer
manipul
stem
cell
capac
limitless
selfrenew
differenti
embryon
stem
cell
pluripot
abil
differenti
cell
type
bodi
wherea
adult
stem
cell
multipot
abil
differenti
sever
cell
type
includ
cell
type
organ
system
stem
cell
provid
three
therapeut
opportun
first
endogen
stem
cell
may
stimul
exogen
administ
growth
factor
keratinocyt
growth
factor
kgf
hepatocyt
growth
factor
transform
growth
factora
tgfa
shown
reduc
effect
ali
anim
model
epiderm
growth
factor
tgfa
kgf
upregul
afc
kgf
potenti
use
effect
includ
cytoprotect
augment
surfact
secret
antioxid
effect
administr
exogen
growth
factor
yet
directli
studi
human
trial
aliard
vascular
endotheli
growth
factor
vegf
promot
angiogenesi
regul
vascular
permeabl
genet
polymorph
vegf
gene
associ
lower
level
vegf
increas
mortal
ali
ard
although
vegf
increas
alveolar
permeabl
aliard
administr
enhanc
alveola
repair
vitro
anim
model
role
vegf
aliard
studi
secondli
administr
exogen
stem
cell
either
embryon
adult
provid
repair
injur
alveolu
anim
studi
promis
lipopolysaccharid
lp
induc
aliard
model
bone
marrow
progenitor
cell
local
site
injuri
differenti
endotheli
epitheli
cell
autolog
transplant
endotheli
progenitor
cell
preserv
endotheli
function
maintain
integr
pulmonari
alveolarcapillari
barrier
wherea
administr
mesenchym
stem
cell
reduc
sever
aliard
mice
patient
pneumonia
aliard
higher
level
endotheli
progenitor
cell
higher
level
correl
improv
outcom
mesenchym
stem
cell
origin
thought
act
sourc
regen
cell
differenti
local
replac
lethal
injur
cell
howev
primari
mechan
action
may
secret
growth
factor
cytokin
signal
molecul
caus
trophic
modul
inflamm
cell
death
fibrosi
tissu
repair
third
role
stem
cell
abil
deliv
gene
therapi
injur
lung
endotheli
progenitor
cell
use
deliv
vasodilatori
gene
pulmonari
vasculatur
result
decreas
paop
experiment
pulmonari
hypertens
one
studi
nontransfect
mesenchym
stem
cell
reduc
sever
aliard
mous
lp
model
wherea
administr
mesenchym
stem
cell
transfect
human
gene
demonstr
small
addit
improv
human
studi
await
nitric
oxid
endogen
vasodil
produc
endothelium
administ
inhal
vasodil
circul
ventil
alveoli
thu
potenti
reduc
shunt
pulmonari
hypertens
earli
studi
demonstr
physiolog
improv
ard
howev
mortal
remain
unchang
two
metaanalys
show
mortal
benefit
report
possibl
harm
due
methemoglobinemia
toxic
nitrogen
compound
increas
pulmonari
edema
rebound
pulmonari
hypertens
renal
failur
expens
possibl
harm
without
mortal
benefit
routin
use
recommend
although
may
place
salvag
therapi
sever
hypoxemia
given
abil
increas
oxygen
prostacylin
deriv
arachidon
acid
potenti
benefici
effect
includ
vasodil
inhibit
platelet
aggreg
reduct
neutrophil
adhes
inhibit
macrophag
neutrophil
activ
inhal
prostaglandin
prostacyclin
compar
inhal
ard
similar
efficaci
advantag
includ
minim
system
effect
absenc
platelet
dysfunct
easi
administr
harmless
metabolit
requir
monitor
placebocontrol
random
trial
yet
studi
ard
ongo
studi
aim
show
nebul
iloprost
decreas
pulmonari
hypertens
select
improv
oxygen
ard
intraven
prostacyclin
form
also
investig
ard
although
vasodilatori
effect
caus
hypotens
increas
pulmonari
shunt
prostacyclin
antiinflammatori
increas
cardiac
output
oxygen
deliveri
improv
oxygen
extract
reduc
oxygen
deliveri
earli
studi
ard
show
signific
benefit
although
dose
deliv
question
reformul
liposom
increas
pulmonari
drug
deliveri
minim
side
effect
despit
promis
preclin
studi
subsequ
studi
neg
potent
vasoconstrictor
implic
pathophysiolog
lung
injuri
tezosentan
endothelin
receptor
antagonist
investig
anim
model
lung
injuri
mix
result
thu
far
almitrin
pulmonari
vasoconstrictor
may
increas
hypox
pulmonari
vasoconstrict
reduc
shunt
small
ard
studi
oxygen
improv
minim
increas
pulmonari
vascular
pressur
combin
intraven
almitrin
decreas
blood
flow
hypox
lung
unit
inhal
increas
blood
flow
ventil
lung
unit
investig
experiment
lung
injuri
small
clinic
studi
found
combin
superior
either
therapi
alon
increas
pao
minim
rise
pulmonari
arteri
pressur
research
requir
imbal
fibrinogenesi
fibrinolysi
ard
result
widespread
fibrin
deposit
alveolar
airspac
interstitium
blood
vessel
pulmonari
intravascular
thrombosi
vasoconstrict
lead
develop
increas
pulmonari
vascular
dead
space
known
independ
predictor
mortal
aliard
sever
anticoagul
propos
potenti
therapi
aliard
undergon
investig
anim
model
tissu
factor
pathway
inhibitor
tfpi
factor
viiai
heparin
antithrombin
iii
activ
protein
c
apc
thrombomodulin
shown
benefici
effect
level
investig
protein
c
level
lower
patient
aliard
normal
control
level
protein
c
correl
clinic
outcom
howev
small
random
control
trial
apc
aliard
reduc
either
durat
ventil
mortal
although
pulmonari
vascular
dead
space
decreas
studi
investig
apc
inflammatori
infecti
aliard
progress
phase
trial
recombin
tfpi
demonstr
improv
lung
dysfunct
score
surviv
therapeut
modul
coagul
system
recommend
aliard
steroid
possess
myriad
antiinflammatori
properti
stretch
genom
macrophag
sever
trial
unsuccess
examin
role
shortcours
highdos
methylprednisolon
prevent
develop
ard
highrisk
patient
trial
highdos
steroid
earli
cours
ard
neg
recent
studi
patient
prolong
lowdos
methylprednisolon
show
reduc
inflamm
organ
dysfunct
plu
reduc
durat
mechan
ventil
icu
stay
excess
alveolar
fibrosi
featur
establish
ard
antifibrot
properti
steroid
investig
set
observ
studi
show
promis
result
follow
small
random
control
trial
suggest
benefici
effect
outcom
howev
ardsnet
late
steroid
rescu
studi
demonstr
overal
effect
mortal
increas
mortal
steroid
commenc
day
onset
aliard
recent
metaanalysi
systemat
review
conclud
steroid
role
prevent
ard
may
role
treat
ard
studi
requir
definit
answer
question
studi
lowdos
steroid
earli
ard
plan
corticosteroid
therapi
cover
detail
chapter
eicosanoid
deriv
arachidon
acid
act
proinflammatori
mediat
produc
activ
either
produc
leukotrien
cyclooxygenas
produc
prostanoid
ketoconazol
imidazol
antifung
agent
antiinflammatori
properti
specif
abil
block
leukotrien
thromboxan
synthesi
antimacrophag
effect
wherebi
proinflammatori
cytokin
secret
reduc
small
studi
report
posit
result
prevent
ard
highrisk
patient
larg
subsequ
studi
ardsnet
group
ketoconazol
patient
ard
demonstr
benefici
effect
ibuprofen
nonsteroid
antiinflammatori
agent
inhibit
cyclooxygenas
larg
sepsi
studi
patient
ibuprofen
diminish
prostanoid
product
associ
trend
toward
decreas
durat
pulmonari
dysfunct
ard
reach
statist
signific
modul
inflammatori
mediat
also
investig
date
treatment
shown
effect
reduc
mortal
complement
contribut
aliard
gener
attract
neutrophil
lung
activ
complement
also
caus
cellular
injuri
product
membran
attack
complex
complement
cell
surfac
receptor
erythrocyt
leukocyt
inhibit
classic
altern
complement
pathway
anim
studi
provid
basi
investig
human
phase
studi
patient
ard
demonstr
safeti
recombin
solubl
cytokin
abil
inhibit
complement
cascad
studi
await
insulin
antiinflammatori
effect
inhibit
proinflammatori
transcript
factor
nfkb
rat
model
endotoxininduc
aliard
tight
glycem
control
mgdl
reduc
sever
lung
injuri
role
intens
insulin
therapi
prevent
aliard
maintain
tight
glycem
control
mgdl
studi
phase
trial
current
studi
potenti
antiinflammatori
treatment
includ
trial
investig
safeti
toler
efficaci
recombin
human
interferonb
aliard
phase
trial
recombin
chimer
monoclon
antibodi
block
cellular
activ
patient
sepsisinduc
ali
trial
recent
termin
result
await
antiinflammatori
therapi
aliard
recommend
nutrit
play
variou
role
manag
ali
ard
use
feed
high
fat
low
carbohydr
reduc
carbon
dioxid
product
thu
ventilatori
requir
enter
nutrit
stimul
gut
lung
immunoglobulin
iga
defens
mechan
polyunsatur
fatti
acid
found
fish
oil
eicosapentaeno
acid
epa
glinolen
acid
gla
docosahexaeno
acid
dha
reduc
product
arachidon
acid
membran
phospholipid
clinic
studi
aliard
demonstr
benefit
fish
oil
supplement
reduct
pulmonari
neutrophil
infiltr
microvascular
permeabl
pulmonari
vascular
resist
durat
ventil
icu
stay
improv
mortal
benefit
fish
oil
supplement
ard
support
recent
systemat
review
immunonutrit
studi
fish
oil
aliard
progress
spain
unit
state
latter
ardsnet
studi
also
investig
earli
versu
late
feed
well
antioxid
ard
studi
inform
use
immunonutrit
aliard
fatti
acidbas
nutrit
may
role
play
manag
aliard
tabl
adhes
immun
cell
endothelium
facilit
diapedesi
vital
step
accumul
neutrophil
alveolu
blockag
adhes
molecul
potenti
therapeut
target
aliard
blockag
neutrophil
adhes
molecul
shown
attenu
develop
experiment
lung
injuri
date
human
studi
pentoxifyllin
phosphodiesteras
inhibitor
antiinflammatori
effect
act
neutrophil
macrophag
small
phase
studi
pentoxifyllin
six
ard
patient
show
advantag
either
ga
exchang
hemodynam
paramet
lisofyllin
pentoxifyllin
deriv
slightli
differ
antiinflammatori
mechan
although
also
inhibit
neutrophil
accumul
downregul
proinflammatori
cytokin
addit
effect
reduc
level
oxid
free
fatti
acid
anim
studi
lisofyllin
treatment
ard
promis
larg
multicent
studi
ardsnet
group
patient
aliard
neg
granulocytemacrophag
colonystimul
factor
gmcsf
involv
develop
homeostasi
alveolar
macrophag
also
play
role
prevent
alveolar
epitheli
apoptosi
small
studi
patient
ali
demonstr
improv
oxygen
gmcsf
period
studi
gmcsf
ard
way
unit
state
activ
neutrophil
releas
neutrophil
elastas
play
key
role
alveolar
injuri
lead
increas
vascular
permeabl
alveolar
flood
neutrophil
elastas
inhibitor
improv
pulmonari
complianc
without
affect
immun
function
pseudomona
aeruginosainduc
pneumonia
rat
phase
multicent
trial
depelestat
ard
complet
await
public
sivelestat
revers
competit
inhibitor
neutrophil
elastas
promis
anim
studi
sivelestat
underw
phase
studi
improv
pulmonari
function
reduc
durat
icu
stay
trend
toward
reduct
durat
mechan
ventil
mortal
howev
intern
sivelestat
trial
ali
patient
requir
mechan
ventil
strive
studi
ali
patient
stop
prematur
increas
allcaus
mortal
rate
note
pulmonari
improv
occur
mortal
rate
reduc
activ
neutrophil
macrophag
partli
exert
injuri
effect
gener
reactiv
oxygen
speci
pulmonari
glutathion
antioxid
reduc
ard
nacetylcystein
procystein
precursor
glutathion
administr
replet
pulmonari
glutathion
level
ard
small
studi
nacetylcystein
aliard
report
mix
result
wherea
studi
procystein
ard
halt
owe
increas
mortal
unpublish
data
nacetylcystein
also
downregul
nfkb
result
reduct
neutrophil
chemoattract
messeng
rna
mrna
alveol
rat
model
lung
injuri
vitamin
c
e
administr
critic
ill
reduc
durat
mechan
ventil
icu
stay
without
decreas
incid
ard
statin
introduc
clinic
practic
cholesterollow
agent
inhibit
hmgcoa
reductas
sinc
shown
possess
pleiotrop
action
depend
independ
hmgcoa
reductas
inhibit
statin
exert
benefici
effect
inflamm
coagul
well
epitheli
endotheli
immun
cell
function
sever
retrospect
studi
demonstr
prior
statin
therapi
associ
improv
surviv
sepsi
includ
pneumonia
patient
aliard
receiv
treatment
statin
admiss
lower
odd
death
although
fail
reach
statist
signific
odd
ratio
confid
interv
p
contrast
anoth
studi
suggest
benefit
recent
studi
shown
pretreat
statin
reduc
pulmonari
marker
inflamm
inhal
lpsinduc
model
lung
injuri
healthi
volunt
ongo
phase
harpprevent
hydroxymethylglutarylcoa
reductas
inhibit
acut
lung
injuri
reduc
pulmonari
oedema
inflamm
harp
studi
investig
effect
simvastatin
prevent
treatment
aliard
inform
area
sever
group
includ
ardsnet
irish
critic
care
trial
group
current
consid
undertak
multicent
studi
address
role
statin
aliard
sar
epidem
led
discoveri
novel
coronaviru
receptor
variant
angiotensinconvert
enzym
ace
implic
reninangiotensin
system
ra
aliard
ace
convert
angiotensin
angiotensin
ii
angiotensin
ii
act
angiotensin
receptor
mediat
vasoconstrict
alveolar
permeabl
lung
injuri
degrad
angiotensin
ii
therefor
excess
ace
activ
delet
associ
wors
lung
injuri
genet
observ
studi
human
support
concept
ra
system
import
develop
outcom
aliard
ace
dd
genotyp
associ
increas
ace
activ
wors
outcom
aliard
retrospect
studi
shown
prior
treatment
ace
inhibitor
associ
decreas
mortal
patient
requir
hospit
communityacquir
pneumonia
therapeut
modul
ra
recombin
ace
inhibit
angiotensin
receptor
blockad
losartan
attenu
pulmonari
inflamm
rodent
model
lpsinduc
aliard
ventilatorinduc
lung
injuri
human
studi
await
hypothermia
decreas
metabol
c
reduc
oxygen
consumpt
carbon
dioxid
product
thu
ventilatori
demand
also
decreas
proinflammatori
gene
transcript
exert
antiinflammatori
effect
anim
model
induc
hypothermia
reduc
express
intracellular
adhes
level
pulmonari
accumul
neutrophil
histolog
lung
damag
sever
case
report
document
success
use
hypothermia
c
sever
aliard
date
one
small
studi
patient
sepsisassoci
sever
aliard
treat
induc
hypothermia
mortal
rate
reduc
mean
temperatur
c
reduct
bodi
temperatur
associ
reduct
alveolararteri
oxygen
gradient
heart
rate
cardiac
index
increas
oxygen
extract
although
interestingli
oxygen
consumpt
remain
unchang
research
requir
despit
repeat
promis
preclin
clinic
phase
studi
therapi
aliard
nonventilatori
strategi
yet
convincingli
shown
improv
outcom
mani
reason
scientif
failur
translat
bench
bedsid
includ
limit
anim
model
poorli
understood
human
factor
studi
methodolog
flaw
use
oxygen
outcom
measur
condit
small
minor
die
refractori
hypoxemia
use
pharmacolog
agent
adjunct
increas
oxygen
allow
limit
injuri
ventil
may
associ
improv
outcom
remain
test
despit
promis
scientif
advanc
nonventilatori
strategi
aliard
remain
elus
best
evid
minim
pulmonari
edema
fluid
restrict
appropri
therapi
may
occasion
justifi
salvag
therapi
sever
aliard
knowledg
risktobenefit
ratio
remain
unclear
